Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

IDXX

Idexx Laboratories, Inc

Feb 13 • 04:00PM ET

629.35

+12.15 1.97 %

Healthcare • Diagnostics & Research • USA • NASD

Peers: ZTS NEOG PAHC LRN ELAN HCSG OHI

| Held by: VTI VOO VO QQQ IVV VUG SPY VOT XLV IWP

Index	NDX, S&P 500	P/E	48.13	EPS (ttm)	13.08	Insider Own	1.10%	Shs Outstand	79.85M	Perf Week	-2.37%
Market Cap	50.25B	Forward P/E	38.26	EPS next Y	16.45	Insider Trans	-2.55%	Shs Float	78.97M	Perf Month	-11.42%
Enterprise Value	50.92B	PEG	3.00	EPS next Q	3.43	Inst Own	92.38%	Short Float	2.30%	Perf Quarter	-11.80%
Income	1.06B	P/S	11.68	EPS this Y	11.18%	Inst Trans	-2.03%	Short Ratio	3.31	Perf Half Y	-3.76%
Sales	4.30B	P/B	32.25	EPS next Y	13.11%	ROA	31.89%	Short Interest	1.81M	Perf YTD	-6.97%
Book/sh	19.52	P/C	279.08	EPS next 5Y	12.75%	ROE	66.20%	52W High	769.98 -18.26%	Perf Year	36.89%
Cash/sh	2.26	P/FCF	47.54	EPS past 3/5Y	17.67% 14.29%	ROIC	53.50%	52W Low	356.14 76.71%	Perf 3Y	26.71%
Dividend Est.	-	EV/EBITDA	35.17	Sales past 3/5Y	8.52% 9.72%	Gross Margin	64.38%	Volatility	3.50% 2.72%	Perf 5Y	15.67%
Dividend TTM	-	EV/Sales	11.83	EPS Y/Y TTM	22.38%	Oper. Margin	31.71%	ATR (14)	19.34	Perf 10Y	827.56%
Dividend Ex-Date	-	Quick Ratio	0.90	Sales Y/Y TTM	10.42%	Profit Margin	24.62%	RSI (14)	35.04	Recom	1.89
Dividend Gr. 3/5Y	- -	Current Ratio	1.23	EPS Q/Q	17.61%	SMA20	-5.33%	Beta	1.67	Target Price	774.92
Payout	0.00%	Debt/Eq	0.53	Sales Q/Q	14.28%	SMA50	-8.33%	Rel Volume	0.99	Prev Close	617.20
Employees	11000	LT Debt/Eq	0.23	Earnings	Feb 02 BMO	SMA200	1.30%	Avg Volume	547.94K	Price	629.35
IPO	Jun 21, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	5.00% 1.67%	Trades		Volume	543,962	Change	1.97%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-09-25	Initiated	Barclays	Overweight	$850
Oct-31-25	Upgrade	Stifel	Hold → Buy	$700
Oct-01-25	Initiated	UBS	Neutral	$720
Aug-05-25	Reiterated	BTIG Research	Buy	$545 → $785
Jul-01-25	Initiated	Jefferies	Buy	$625
Dec-02-24	Initiated	Leerink Partners	Outperform	$500
Jul-25-24	Initiated	BTIG Research	Buy	$580
Jan-30-24	Downgrade	Piper Sandler	Overweight → Neutral	$525
Dec-07-23	Initiated	Exane BNP Paribas	Outperform	$602
Dec-04-23	Upgrade	Cleveland Research	Neutral → Buy
Aug-02-23	Downgrade	Atlantic Equities	Overweight → Neutral	$610
Jul-25-22	Downgrade	Stifel	Buy → Hold	$415
Jul-21-22	Upgrade	Goldman	Neutral → Buy	$530 → $435
Jul-12-22	Initiated	Piper Sandler	Overweight	$440
May-05-22	Downgrade	BofA Securities	Buy → Neutral	$550 → $470
Feb-08-22	Initiated	Atlantic Equities	Overweight	$650
Nov-18-21	Initiated	Morgan Stanley	Overweight
Aug-05-21	Resumed	Credit Suisse	Outperform	$735
Jul-12-21	Downgrade	Guggenheim	Buy → Neutral
Feb-17-21	Initiated	Barclays	Overweight	$600

Show Previous Ratings

Feb-13-26 09:04PM	Analyst Report: IDEXX Laboratories, Inc. (Morningstar Research)
Feb-12-26 04:15PM	IDEXX Laboratories to Present at Two Institutional Investor Conferences (Business Wire)
Feb-11-26 08:45AM	Baron Partners Fund is Leveraging IDEXX Laboratories' (IDXX) Long-Term Growth Drivers (Insider Monkey)
Feb-10-26 09:45AM	Here's Why Idexx Laboratories (IDXX) is a Strong Growth Stock (Zacks)
Feb-07-26 11:12AM	IDEXX Laboratories, Inc. (IDXX): A Bull Case Theory (Insider Monkey)
09:22AM	Loading…
Feb-05-26 09:22AM	IDEXX Laboratories (IDXX) Positioned to Benefit from Growing Aging Pet Market (Insider Monkey)
08:56AM	Fidelity Growth Strategies Fund Avoids IDEXX Laboratories (IDXX) Due to Questionable Growth Durability (Insider Monkey)
Feb-04-26 11:55AM	Reasons to Hold Veeva Systems Stock in Your Portfolio for Now (Zacks)
11:40AM	IQV or IDXX: Which Is the Better Value Stock Right Now? (Zacks)
Feb-03-26 10:29AM	Natera Files Signatera CDx PMA With FDA for Bladder Cancer MRD Test (Zacks)
Feb-02-26 04:26PM	Stock Market Today: Dow Jumps As Trump Touts This Deal; Robinhood Plunges But Palantir Pops (Live Coverage) (Investor's Business Daily)
04:25PM	Idexx Tumbles Following An 'Impressive' Report; Can It Shake Pet-Health Challenges? (Investor's Business Daily)
04:06PM	Analyst Report: IDEXX Laboratories, Inc. (Morningstar Research)
04:00PM	IDEXX Laboratories Inc (IDXX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
01:40PM	Russell 2000 Rallies, Gold And Silver Extend Losses: What's Moving Markets Monday? (Benzinga)
01:05PM	Loading…
01:05PM	Why Is IDEXX Labs Stock Falling Today? (Benzinga)
12:52PM	IDEXX Laboratories Q4 Earnings Call Highlights (MarketBeat)
11:19AM	Stocks Gain on US Manufacturing Strength (Barchart)
10:14AM	Stock Indexes Climb as Chip Makers and AI Infrastructure Stocks Rebound (Barchart)
09:51AM	Here's Why You Should Add Inogen Stock to Your Portfolio Now (Zacks)
09:42AM	IDEXX Stock Down Despite Q4 Earnings & Revenue Beat, Margins Rise (Zacks)
09:30AM	Idexx (IDXX) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:52AM	Idexx Laboratories Stock Topples Despite Its 'Impressive' Report (Investor's Business Daily)
07:40AM	Idexx Laboratories (IDXX) Beats Q4 Earnings and Revenue Estimates (Zacks)
06:48AM	Idexx: Q4 Earnings Snapshot (Associated Press Finance)
06:48AM	IDEXX Laboratories Guides FY26 In Line With Estimates - Update (RTT News)
06:30AM	IDEXX Laboratories Announces Fourth Quarter and Full Year 2025 Results (Business Wire)
Feb-01-26 07:47AM	January jobs data, Alphabet and Amazon earnings, more Warsh fallout: What to watch this week (Yahoo Finance)
Jan-31-26 09:36AM	IDEXX Laboratories, Inc. (IDXX): Innovation and Seamless Leadership Transition Drive 2026 Outlook (Insider Monkey)
Jan-30-26 12:07PM	SENS Stock Up as Eversense 365 CGM Wins European CE Mark Approval (Zacks)
12:47PM	Loading…
Jan-29-26 12:47PM	Reasons to Add AngioDynamics Stock to Your Portfolio for Now (Zacks)
12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX) (Zacks)
Jan-28-26 12:35PM	Here's Why You Should Retain Ecolab Stock in Your Portfolio Now (Zacks)
12:31PM	OM Stock Gains on FDA Clearance for Next-Gen Tablo Dialysis System (Zacks)
09:15AM	Curious about Idexx (IDXX) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
07:43AM	Here's How IDEXX Laboratories Is Placed Ahead of Q4 Earnings (Zacks)
Jan-27-26 11:47AM	BDX Introduces BD Research Cloud 7.0 for Advanced Flow Cytometry (Zacks)
Jan-23-26 11:43AM	ISRG Stock Gains on Q4 Earnings & Revenue Beat, Gross Margin Declines (Zacks)
Jan-22-26 12:32PM	Here's Why You Should Retain INSP Stock in Your Portfolio for Now (Zacks)
Jan-21-26 10:49AM	CAPR Updates FDA on Deramiocel BLA, Plans HOPE-3 CSR Filing in February (Zacks)
07:58AM	Here's Why You Should Retain Revvity Stock in Your Portfolio for Now (Zacks)
07:54AM	Is IDEXX Laboratories Stock the Right Pick for Your Portfolio Now? (Zacks)
Jan-19-26 04:27PM	Top Research Reports for GE Aerospace, KLA & Parker-Hannifin (Zacks)
12:34PM	SNN Boosts Shoulder Repair Portfolio With Integrity Orthopaedics Deal (Zacks)
12:31PM	Here's Why You Should Hold DaVita Stock in Your Portfolio for Now (Zacks)
Jan-15-26 10:53AM	Masimo Stock Declines Despite Solid Preliminary Q4 Revenues (Zacks)
10:37AM	Reasons to Retain QuidelOrtho Stock in Your Portfolio for Now (Zacks)
10:35AM	PacBio Stock Up on HiFi Sequencing Adoption for Major SUDC Research (Zacks)
08:24AM	BSX Stock May Gain From Newly Inked Deal to Buy Valencia Technologies (Zacks)
07:15AM	Lowest-Dose Radiography Meets Next-Level Imaging: IDEXX Launches ImageVue DR50 Plus (Business Wire)
07:00AM	IDEXX Advances the Future of Veterinary Cancer Care with Comprehensive Mast Cell Tumor Testing for Dogs (Business Wire)
Jan-14-26 10:48AM	Reasons to Retain TransMedics Stock in Your Portfolio for Now (Zacks)
10:44AM	Baxter Unveils Dynamo Smart Stretcher to Improve Hospital Safety (Zacks)
Jan-13-26 08:30AM	IDEXX Announces CEO Succession (Business Wire)
07:39AM	IDEXX Laboratories (IDXX): From a Detractor to a Revivor (Insider Monkey)
06:16AM	RxSight (RXST) Soars 14.1%: Is Further Upside Left in the Stock? (Zacks)
Jan-12-26 08:09AM	Illumina's New Connected Multiomics Platform Set to Boost Its Stock (Zacks)
Jan-09-26 05:22PM	IBD Stock Of The Day: Pet-Health Firm Idexx Laboratories Looks To Build On 2025 Rally (Investor's Business Daily)
01:30PM	IDEXX Laboratories to Release 2025 Fourth Quarter and Full Year Financial Results (Business Wire)
11:20AM	PacBio Stock Dips Post Latest Launch to Expand Multiomics Capabilities (Zacks)
Jan-08-26 09:46AM	INGN Stock Gains Post Latest Launch to Expand Respiratory Care Suite (Zacks)
Jan-07-26 07:25AM	IDEXX Stock Up 64.7% in a Year: What's Driving the Growth? (Zacks)
Jan-05-26 10:37AM	What to Expect From IDEXX Laboratories Next Quarterly Earnings Report? (Barchart)
Dec-31-25 07:31AM	Here's Why You Should Retain CONMED Stock in Your Portfolio Now (Zacks)
Dec-30-25 12:48PM	3 ESG Stocks to Add to Your Portfolio for Sustainable Returns in 2026 (Zacks)
05:48AM	Zacks Industry Outlook Highlights Veracyte, IDEXX Laboratories and Intuitive Surgical (Zacks)
Dec-29-25 09:40AM	Is IDEXX Laboratories (IDXX) Stock Outpacing Its Medical Peers This Year? (Zacks)
07:23AM	3 Medical Instrument Stocks to Counter Industry Woes Using GenAI (Zacks)
Dec-18-25 02:00PM	Intel, Paramount are some of Wall Street's best comebacks of 2025 (Yahoo Finance Video)
Dec-15-25 12:52PM	This S&P 500 Stock Has Wall Street Wagging Its Tail (Investor's Business Daily)
07:54AM	4 Medical Device Stocks to Buy for Healthy Returns in 2026 (Zacks)
Dec-04-25 11:46AM	HIMS Stock Jumps After Buyout Deal, Boosts Blood Collection Efficiency (Zacks)
11:43AM	IDEXX Laboratories Stock Rallies 75.6% YTD: What's Behind the Surge? (Zacks)
08:34AM	Here's Why You Should Add CONMED Stock to Your Portfolio Now (Zacks)
02:29AM	How Is IDEXX Laboratories Stock Performance Compared to Other Health Care Stocks? (Barchart)
Dec-03-25 11:30AM	Idexx (IDXX) Up 1.5% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-02-25 08:26AM	Baxter Issues Recall Notice for Permanent Removal of Life2000 Ventilation (Zacks)
Dec-01-25 05:12PM	Stocks To Watch As Google Drives Rattled But Rebounding Market (Investor's Business Daily)
01:46PM	Analyst Report: IDEXX Laboratories, Inc. (Morningstar Research)
09:14AM	Nyxoah Gains Favorable CMS Reimbursement Ruling for Genio System (Zacks)
08:30AM	If You Invested $1000 in Idexx Laboratories 10 Years Ago, This Is How Much You'd Have Now (Zacks)
Nov-28-25 12:00PM	What Makes Idexx Laboratories (IDXX) a Strong Momentum Stock: Buy Now? (Zacks)
12:00PM	Idexx (IDXX) Upgraded to Buy: Here's What You Should Know (Zacks)
Nov-26-25 09:09AM	GEHC Stock Gains Post Latest Launch to Optimize Radiology Workflows (Zacks)
Nov-21-25 12:45PM	3 Reasons Why Growth Investors Shouldn't Overlook Idexx (IDXX) (Zacks) +5.30%
08:47AM	What Are Wall Street Analysts' Target Price for IDEXX Laboratories Stock? (Barchart)
Nov-20-25 02:36PM	Bruker Stock Earns Relative Strength Rating Upgrade (Investor's Business Daily)
09:35AM	Idexx Laboratories (IDXX) Recently Broke Out Above the 20-Day Moving Average (Zacks)
Nov-17-25 01:13PM	Molina Secures Deal From AHCA to Serve Florida's Medicaid Members (Zacks)
Nov-14-25 09:03AM	Pet Healthcare Spending Is Soaring. These 5 Stocks Are Positioned to Clean Up (24/7 Wall St.)
Nov-13-25 08:08AM	TFX Stock Falls Despite Q3 Earnings and Revenue Beat, '25 View Down (Zacks)
Nov-12-25 07:13AM	ALC's Q3 Earnings Beat, Revenues Miss, Stock Rises in After-Market Hours (Zacks)
Nov-11-25 07:26AM	VCYT Stock Gains on Q3 Earnings and Revenue Beat, '25 View Up (Zacks)
Nov-10-25 09:03AM	Here's Why IDEXX Laboratories (IDXX) Surged in Q3 (Insider Monkey)
Nov-06-25 08:29AM	STE Stock Gains on Q2 Earnings and Revenue Beat, '26 EPS View Up (Zacks)
08:00AM	November Is The Best Month And 5 Stocks Are Already On Fire (Investor's Business Daily)
07:26AM	Here's Why Baron Focused Growth Fund Invested in IDEXX Laboratories (IDXX) (Insider Monkey)
Nov-05-25 12:17PM	Zimmer Biomet Q3 Earnings Top but Revenue Miss Causes Pre-Market Drop (Zacks)
11:01AM	TEM's Q3 Earnings & Revenues Beat, Stock Down in After-Market Hours (Zacks)
10:52AM	TECH Stock Falls on Q1 Earnings Meet, Revenues Miss, Margins Up (Zacks)

IDEXX Laboratories, Inc. engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy, and water testing markets. It operates through the following segments: Companion Animal Group (CAG), Water Quality Products (Water), Livestock, Poultry, and Dairy (LPD), and Other. The CAG segment provides diagnostic and information management-based products and services for the companion animal veterinary industry, including in-clinic diagnostic solutions, outside reference laboratory services, and veterinary software and services. The Water segment offers innovative testing solutions for easy, rapid, and accurate detection and quantification of various microbiological parameters in water. The LPD segment develops diagnostic tests, services, and related instrumentation that are used to manage the health status of livestock and poultry, to improve producer efficiency, and to ensure the quality and safety of milk and food. The Other segment is composed of products for the human point-of-care medical diagnostics market with its out-licensing arrangements. The company was founded by David Evans Shaw on December 19, 1983, and is headquartered in Westbrook, ME.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
FENNELL GEORGE	Executive Vice President	Feb 10 '26	Option Exercise	67.85	11,345	769,758	21,168	Feb 11 05:01 PM
FENNELL GEORGE	Executive Vice President	Feb 09 '26	Option Exercise	67.85	1,476	100,147	9,823	Feb 11 05:01 PM
FENNELL GEORGE	Executive Vice President	Feb 10 '26	Sale	646.72	11,345	7,336,993	9,823	Feb 11 05:01 PM
GEORGE FENNELL	Officer	Feb 10 '26	Proposed Sale	646.72	11,345	7,336,994		Feb 10 04:05 PM
Hunt Nimrata	Executive Vice President	Nov 07 '25	Option Exercise	382.28	12,530	4,789,947	30,574	Nov 10 05:01 PM
Hunt Nimrata	Executive Vice President	Nov 07 '25	Sale	703.34	9,425	6,629,014	21,149	Nov 10 05:01 PM
NIMRATA K HUNT	Officer	Nov 07 '25	Proposed Sale	703.35	9,425	6,629,060		Nov 07 04:07 PM
Smith Martin Alexander	Executive Vice President	Sep 01 '25	Option Exercise	0.00	18	0	1,439	Sep 03 05:56 PM
SZOSTAK M ANNE	Director	Aug 22 '25	Option Exercise	206.62	2,187	451,878	2,449	Aug 26 05:00 PM
SZOSTAK M ANNE	Director	Aug 22 '25	Sale	647.33	2,187	1,415,700	262	Aug 26 05:00 PM
MARGARET ANNE SZOSTAK	Director	Aug 22 '25	Proposed Sale	647.33	2,187	1,415,700		Aug 22 04:06 PM
Erickson Michael G	Executive Vice President	Aug 12 '25	Sale	649.96	406	263,813	11,287	Aug 14 06:01 PM
Hunt Nimrata	Executive Vice President	Aug 12 '25	Option Exercise	244.16	1,226	299,344	18,033	Aug 13 05:17 PM
Hunt Nimrata	Executive Vice President	Aug 11 '25	Sale	656.53	1,200	787,840	16,807	Aug 13 05:17 PM
MICHAEL G ERICKSON	Officer	Aug 12 '25	Proposed Sale	649.96	407	264,534		Aug 12 06:32 PM
Underberg Sharon E.	EVP, GC & Corporate Secretary	Aug 08 '25	Option Exercise	206.94	5,450	1,127,823	11,606	Aug 12 05:00 PM
Underberg Sharon E.	EVP, GC & Corporate Secretary	Aug 12 '25	Option Exercise	544.08	183	99,567	6,339	Aug 12 05:00 PM
Underberg Sharon E.	EVP, GC & Corporate Secretary	Aug 08 '25	Sale	651.60	5,450	3,551,220	6,156	Aug 12 05:00 PM
MAZELSKY JONATHAN JAY	President and CEO	Aug 08 '25	Option Exercise	598.49	183	109,523	83,494	Aug 12 05:00 PM
Emerson Andrew	EVP, CFO and Treasurer	Aug 07 '25	Option Exercise	141.60	1,849	261,818	4,273	Aug 11 06:00 PM
NIMRATA K HUNT	Officer	Aug 11 '25	Proposed Sale	656.53	1,200	787,840		Aug 11 04:04 PM
Hunt Nimrata	Executive Vice President	Aug 06 '25	Option Exercise	187.57	12,794	2,399,798	25,150	Aug 08 09:00 PM
Hunt Nimrata	Executive Vice President	Aug 06 '25	Sale	630.43	7,143	4,503,163	18,007	Aug 08 09:00 PM
MAZELSKY JONATHAN JAY	President and CEO	Aug 06 '25	Option Exercise	67.85	29,260	1,985,291	112,571	Aug 08 08:38 PM
MAZELSKY JONATHAN JAY	President and CEO	Aug 06 '25	Sale	631.98	29,260	18,491,642	83,311	Aug 08 08:38 PM
Lane Michael	Executive Vice President	Aug 06 '25	Option Exercise	276.27	8,411	2,323,682	15,543	Aug 08 08:37 PM
Lane Michael	Executive Vice President	Aug 06 '25	Sale	627.74	8,411	5,279,893	7,132	Aug 08 08:37 PM
SHARON E UNDERBERG	Officer	Aug 08 '25	Proposed Sale	651.60	5,450	3,551,220		Aug 08 04:23 PM
NIMRATA K HUNT	Officer	Aug 06 '25	Proposed Sale	630.43	7,143	4,503,161		Aug 06 04:32 PM
JONATHAN J MAZELSKY	Officer	Aug 06 '25	Proposed Sale	631.98	29,260	18,491,641		Aug 06 04:13 PM
MICHAEL J LANE	Officer	Aug 06 '25	Proposed Sale	627.74	8,411	5,279,893		Aug 06 04:13 PM
Johnson Michael Perkins	Executive Vice President	Jun 01 '25	Option Exercise	0.00	3,382	0	3,864	Jun 03 05:00 PM
SZOSTAK M ANNE	Director	May 21 '25	Option Exercise	160.28	1,046	167,653	1,308	May 23 05:00 PM
SZOSTAK M ANNE	Director	May 21 '25	Sale	512.34	1,260	645,545	1,801	May 23 05:00 PM
SZOSTAK M ANNE	Director	May 21 '25	Sale	513.74	1,046	537,372	262	May 23 05:00 PM
SZOSTAK M ANNE	Director	May 21 '25	Proposed Sale	517.16	1,260	651,621		May 21 04:00 PM
JUNIUS DANIEL M	Director	May 13 '25	Option Exercise	263.81	2,683	707,801	5,987	May 14 05:00 PM
JUNIUS DANIEL M	Director	May 13 '25	Sale	506.41	2,683	1,358,697	3,304	May 14 05:00 PM
JUNIUS DANIEL M	Director	May 13 '25	Proposed Sale	506.41	2,683	1,358,697		May 13 07:32 PM
Vandebroek Sophie V.	Director	May 09 '25	Option Exercise	283.59	1,279	362,712	2,446	May 13 05:00 PM
Vandebroek Sophie V.	Director	May 09 '25	Sale	491.34	1,279	628,425	1,167	May 13 05:00 PM
Vandebroek Sophie V.	Director	May 09 '25	Proposed Sale	491.34	1,279	628,425		May 09 04:18 PM
Vandebroek Sophie V.	Director	May 06 '25	Option Exercise	0.00	262	0	1,167	May 08 07:01 PM
SZOSTAK M ANNE	Director	May 06 '25	Option Exercise	0.00	262	0	262	May 08 07:01 PM
Kingsley Lawrence D	Director	May 06 '25	Option Exercise	0.00	346	0	9,229	May 08 07:01 PM
JUNIUS DANIEL M	Director	May 06 '25	Option Exercise	0.00	262	0	3,304	May 08 07:01 PM
ESSIG STUART	Director	May 06 '25	Option Exercise	0.00	262	0	2,236	May 08 07:00 PM
COLLINS Asha	Director	May 02 '25	Proposed Sale	497.63	2,671	1,329,167		May 02 04:19 PM

Peers: AMGN LLY MRK JNJ PFE BIIB BMY VRTX GILD REGN

| Held by: IJR AVUV VTI IWM XBI VB FBT VBK SPSM VXF

Index	RUT	P/E	16.41	EPS (ttm)	2.02	Insider Own	2.33%	Shs Outstand	165.10M	Perf Week	-5.01%
Market Cap	5.48B	Forward P/E	18.95	EPS next Y	1.75	Insider Trans	-2.66%	Shs Float	161.27M	Perf Month	8.30%
Enterprise Value	4.44B	PEG	-	EPS next Q	0.41	Inst Own	107.16%	Short Float	11.78%	Perf Quarter	5.59%
Income	338.83M	P/S	3.60	EPS this Y	-39.79%	Inst Trans	2.48%	Short Ratio	9.50	Perf Half Y	17.34%
Sales	1.52B	P/B	3.16	EPS next Y	0.56%	ROA	15.08%	Short Interest	19.00M	Perf YTD	18.51%
Book/sh	10.50	P/C	4.93	EPS next 5Y	-14.29%	ROE	22.35%	52W High	36.45 -9.03%	Perf Year	-7.89%
Cash/sh	6.73	P/FCF	11.15	EPS past 3/5Y	- -	ROIC	18.84%	52W Low	25.17 31.77%	Perf 3Y	28.82%
Dividend Est.	-	EV/EBITDA	11.41	Sales past 3/5Y	9.89% 5.87%	Gross Margin	85.66%	Volatility	2.86% 3.47%	Perf 5Y	76.41%
Dividend TTM	-	EV/Sales	2.92	EPS Y/Y TTM	3.40%	Oper. Margin	23.57%	ATR (14)	1.15	Perf 10Y	9.93%
Dividend Ex-Date	-	Quick Ratio	3.27	Sales Y/Y TTM	1.08%	Profit Margin	22.27%	RSI (14)	51.69	Recom	1.44
Dividend Gr. 3/5Y	- -	Current Ratio	3.67	EPS Q/Q	-11.21%	SMA20	-2.04%	Beta	0.52	Target Price	43.81
Payout	0.00%	Debt/Eq	0.04	Sales Q/Q	4.24%	SMA50	7.51%	Rel Volume	0.49	Prev Close	33.29
Employees	1800	LT Debt/Eq	0.04	Earnings	Feb 25 BMO	SMA200	11.13%	Avg Volume	2.00M	Price	33.16
IPO	Jul 16, 1991	Option/Short	Yes / Yes	EPS/Sales Surpr.	85.55% 10.45%	Trades		Volume	989,058	Change	-0.39%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-11-25	Initiated	Truist	Buy	$50
Sep-26-25	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$44
Sep-03-25	Initiated	Wells Fargo	Overweight	$44
Jul-15-25	Initiated	Goldman	Buy	$43
Jun-17-25	Upgrade	UBS	Neutral → Buy	$42
May-28-25	Initiated	Needham	Buy	$45
Mar-13-25	Initiated	RBC Capital Mkts	Sector Perform	$40
Mar-04-25	Upgrade	UBS	Sell → Neutral	$21 → $38
Feb-11-25	Initiated	Deutsche Bank	Buy	$40
Nov-05-24	Upgrade	Stifel	Hold → Buy	$25 → $36
Jun-17-24	Initiated	TD Cowen	Buy	$34
Mar-19-24	Initiated	Robert W. Baird	Outperform	$37
Feb-20-24	Downgrade	UBS	Neutral → Sell	$25
Nov-20-23	Resumed	JP Morgan	Neutral	$33
Oct-24-23	Upgrade	Evercore ISI	In-line → Outperform
Oct-17-23	Initiated	UBS	Neutral	$31
Nov-03-22	Upgrade	Piper Sandler	Neutral → Overweight	$26 → $30
Oct-14-22	Upgrade	BofA Securities	Underperform → Neutral	$27 → $25
Aug-16-22	Initiated	Piper Sandler	Neutral	$26
Apr-22-22	Resumed	Goldman	Buy	$35

Show Previous Ratings

Feb-13-26 01:11PM	Waters Q4 Earnings Surpass Estimates, Revenues Increase Y/Y (Zacks)
12:55PM	SNY Stock Falls After Board Suddenly Makes Leadership Change (Zacks)
11:53AM	VRTX's Q4 Earnings Miss Mark, Revenues Beat on Higher Product Sales (Zacks)
10:33AM	Agios Pharmaceuticals Incurs Narrower-Than-Expected Q4 Loss (Zacks)
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
10:20AM	Loading…
10:20AM	NVS Reports Positive Late-Stage Data on Kidney Disease Drug Vanrafia (Zacks)
10:19AM	ALNY Q4 Earnings Beat, Sales Miss Despite Y/Y Growth, Stock Down (Zacks)
10:04AM	CRSP Posts Wider-Than-Expected Loss in Q4, Sales Miss Estimates (Zacks)
Feb-12-26 10:38AM	MDGL Strengthens MASH Franchise With New Genetic Approaches (Zacks)
10:30AM	Zoetis Stock Gains After Q4 Earnings & Revenues Beat Estimates (Zacks)
07:30AM	Alkermes plc Completes Acquisition of Avadel Pharmaceuticals plc, Accelerating Entry Into Sleep Medicine Market (Business Wire)
Feb-11-26 04:00PM	Alkermes to Report Fourth Quarter and Year-End Financial Results on Feb. 25, 2026 (Business Wire)
12:57PM	Pharma companies left out of Trump's drug-pricing deals look for way in (Reuters)
10:45AM	MRNA Down Nearly 10% as FDA Refuses to Review Influenza Vaccine BLA (Zacks)
Feb-10-26 10:43AM	SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status (Zacks)
10:38AM	Loading…
10:38AM	INCY Q4 Earnings Miss Estimates, Revenues Beat on Higher Product Sales (Zacks)
Feb-09-26 11:42AM	IMVT Posts Narrower-Than-Expected Q3 Loss, Pipeline in Focus (Zacks)
Feb-06-26 01:58PM	Mettler-Toledo Q4 Earnings Top Estimates, Sales Rise Y/Y (Zacks)
11:45AM	GSK Gets EU Approval for Expanded Use of Nucala in COPD (Zacks)
11:31AM	KOD Stock Up 24% in 3 Months: Here's What You Need to Know (Zacks)
Feb-05-26 11:42AM	Verastem Stock Rises Nearly 8% on Strong Q4 & 2025 Preliminary Results (Zacks)
10:49AM	Bristol-Myers Stock Up as Q4 Earnings and Revenues Beat Estimates (Zacks)
Feb-04-26 10:11AM	FDA Rejects AZN's Saphnelo SubQ Formulation, Priority Tag to Datroway (Zacks)
09:16AM	NVO Q4 Earnings & Sales Beat Estimates, Stock Down on Poor 2026 View (Zacks)
Feb-03-26 11:59AM	Sanofi's Venglustat Meets Primary Endpoints in Gaucher Disease Study (Zacks)
11:36AM	MRK Q4 Earnings & Sales Beat Estimates, Stock Down on Weak '26 View (Zacks)
10:43AM	NVO's CagriSema Outshines Semaglutide in Phase III Diabetes Study (Zacks)
09:27AM	Here's Why Gilead Sciences Stock Surged 21% in a Month (Zacks)
07:52AM	Acadia Expects Negative CHMP Opinion for Rett Syndrome Drug in EU (Zacks)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
09:40AM	Loading…
09:40AM	Is Alkermes (ALKS) Outperforming Other Medical Stocks This Year? (Zacks)
Jan-30-26 10:24AM	FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug (Zacks)
10:11AM	KYMR Initiates Dosing in Mid-Stage Asthma Study of Lead Candidate (Zacks)
Jan-29-26 11:52AM	HALO Rises Nearly 4% on Strong 2025 Preliminary Data and 2026 Guidance (Zacks)
11:23AM	TEVA's Q4 Earnings Beat, Branded Drugs Drive Revenue Growth (Zacks)
08:53AM	Biogen's Autoimmune Disease Candidate Gets FDA's Breakthrough Status (Zacks)
08:34AM	Are Options Traders Betting on a Big Move in Alkermes Stock? (Zacks)
Jan-28-26 09:45AM	NTLA Stock Up More Than 6% as FDA Lifts ATTRv-PN Study Clinical Hold (Zacks)
Jan-27-26 02:07PM	BHC's Late-Stage Liver Cirrhosis Studies Fail, Stock Down (Zacks)
12:15PM	Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why (Zacks)
10:53AM	RVMD Stock Tumbles as MRK Reportedly Withdraws Buyout Offer (Zacks)
10:50AM	SRPT Stock Up 8% on Positive Long-Term Data From Elevidys Study in DMD (Zacks)
Jan-23-26 11:13AM	CORT Rises as Relacorilant Meets OS Endpoint in Ovarian Cancer Study (Zacks)
Jan-22-26 02:17PM	Alkermes Stock Earns Technical Rating Upgrade (Investor's Business Daily)
11:39AM	MRNA & MRK's Personalized Cancer Therapy Delivers Strong 5-Year Data (Zacks)
03:09AM	Jim Cramer on Alkermes: "I Think It's a Hold, Maybe a Weak One" (Insider Monkey)
Jan-21-26 10:46AM	ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission (Zacks) +6.61%
10:31AM	FDA Grants Breakthrough Therapy Tag to LLY's Ovarian Cancer Candidate (Zacks)
10:12AM	NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies (Zacks)
Jan-19-26 10:36AM	ImmunityBio Shares Surge on Updated Durable Lymphoma Study Results (Zacks)
09:17AM	CytomX Stock Rises 31% in a Month: Here's What You Should Know (Zacks)
Jan-16-26 08:28PM	Lightning Round: Medline is 'unbelievable', it's a buy, says Jim Cramer (CNBC TV)
11:08AM	Mirum Stock Rises 7% in a Week: Here's What You Should Know (Zacks)
09:06AM	Erasca Stock Surges 42% in a Week: Here's What You Should Know (Zacks)
Jan-15-26 11:16AM	Apellis Stock Crashes 23% in a Week: Here's What You Should Know (Zacks)
09:40AM	Are Medical Stocks Lagging Alkermes (ALKS) This Year? (Zacks)
Jan-14-26 12:10PM	Will Alkermes (ALKS) Beat Estimates Again in Its Next Earnings Report? (Zacks) +5.04%
10:18AM	PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific (Zacks)
03:33AM	Best Value Stocks to Buy for Jan.14 (Zacks)
Jan-13-26 06:23PM	Alkermes Touts $10B Sleep Market as ALKS 2680 Heads to Phase 3, Avidel Deal Nears Close (MarketBeat)
Jan-07-26 11:45AM	FDA Grants Breakthrough Therapy Designation to ALKS' Narcolepsy Drug (Zacks)
Jan-06-26 07:00AM	Alixorexton Granted Breakthrough Therapy Designation by U.S. FDA for the Treatment of Narcolepsy Type 1 (Business Wire)
Dec-30-25 04:00PM	Alkermes to Present at the 44th Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-22-25 06:50AM	Why Analysts are Rating Alkermes (ALKS) a Buy (Insider Monkey)
Dec-08-25 09:40AM	Are Investors Undervaluing Alkermes (ALKS) Right Now? (Zacks)
Nov-27-25 11:30AM	Why Is Alkermes (ALKS) Down 5.5% Since Last Earnings Report? (Zacks)
Nov-25-25 04:00PM	Alkermes to Participate in Two Upcoming Investor Conferences (Business Wire)
Nov-20-25 12:33PM	AGIO Stock Hits 52-Week Low on Mixed Sickle Cell Disease Study Results (Zacks)
09:14AM	ALKS Raises Its Offer to Buy Avadel In Response to Lundbeck's Proposal (Zacks)
Nov-19-25 04:22PM	Alkermes Ups Its Avadel Bid To $2.37 Billion In A Buyout Battle With Lundbeck (Investor's Business Daily)
01:44PM	Alkermes prevails over Lundbeck in Avadel bidding war (Pharmaceutical Technology)
10:59AM	Insmed Stock Rise on EU Nod for Lung Disease Drug, Brinsupri (Zacks)
09:12AM	Looking for Earnings Beat? Buy These 5 Top-Ranked Stocks (Zacks)
08:53AM	BAYRY Obtains Approval for Hormone Free VMS Treatment Lynkuet in the EU (Zacks)
06:00AM	Alkermes plc Announces Increased Offer to Acquire Avadel Pharmaceuticals plc (PR Newswire)
05:33AM	Alkermes escalates bidding war; US biotech risks falling behind China (BioPharma Dive)
12:25AM	TD Cowen Asserts Buy Rating as Alkermes plc (ALKS) Delivers Topline Results for Narcolepsy Treatment (Insider Monkey)
Nov-18-25 01:23PM	RHHBY Reports Positive Phase III Data on Breast Cancer Drug (Zacks)
12:16PM	JAZZ Hits 52-Week High on Encouraging Gastric Cancer Study Data (Zacks)
10:36AM	Avadel Board Labels Lundbeck Acquisition Bid a Superior Proposal (Zacks)
Nov-17-25 09:32AM	FDA Restricts Use of Sarepta's Gene Therapy, Adds Safety Warnings (Zacks)
Nov-14-25 12:39PM	Health Care Roundup: Market Talk (The Wall Street Journal) -6.35%
11:38AM	To Wall Street, a new bidding war puts Alkermes in a tough spot (BioPharma Dive)
09:40AM	H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal (The Wall Street Journal)
09:19AM	Avadel Surges 20% On Lundbeck's Surprise Alkermes-Topping Bid (Investor's Business Daily)
08:11AM	GILD's Investigational Regimen for HIV Treatment Meets Primary Goal (Zacks)
07:45AM	Alkermes Response to Avadel Announcement (PR Newswire)
06:06AM	Lundbeck sparks bidding war with Alkermes; Pfizer closes Metsera deal (BioPharma Dive)
Nov-13-25 01:46PM	Cytokinetics Gains 11.4% in a Week: Is There More Room for Growth? (Zacks)
Nov-12-25 12:16PM	Narcolepsy race heats up with Alkermes OX2R NT2 data but investors spooked (Clinical Trials Arena) -7.11%
09:35AM	DraftKings downgraded, Instacart upgraded: Wall Streets top analyst calls (TipRanks)
07:30AM	Alkermes Announces Positive Topline Results From Vibrance-2 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 2 (PR Newswire)
Nov-11-25 12:52PM	Immunovant's Q2 Loss Wider Than Expected, Pipeline in Focus (Zacks)
11:40AM	ALKS or ILMN: Which Is the Better Value Stock Right Now? (Zacks)
09:32AM	DraftKings downgraded, Instacart upgraded: Wall Street's top analyst calls (The Fly)
09:00AM	CRSP Posts Narrower-Than-Expected Loss in Q3, Sales Miss Estimates (Zacks)
Nov-07-25 01:45PM	IOVA Soars 28% on Narrower-Than-Expected Loss in Q3, Revenues Up Y/Y (Zacks)
01:23PM	DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug (Zacks)
11:20AM	Allogene Posts Narrower-Than-Expected Loss in Q3, Nil Sales (Zacks)
09:55AM	Does Alkermes (ALKS) Have the Potential to Rally 36.3% as Wall Street Analysts Expect? (Zacks)

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 02 '26	Option Exercise	19.34	5,000	96,700	66,740	Feb 02 08:52 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Feb 02 '26	Sale	33.93	9,000	305,384	57,740	Feb 02 08:52 PM
Cooke Shane	Director	Feb 02 '26	Option Exercise	31.64	61,200	1,936,368	164,944	Feb 02 08:48 PM
Cooke Shane	Director	Feb 02 '26	Sale	34.57	61,200	2,115,673	103,744	Feb 02 08:48 PM
Cooke Shane	Officer	Feb 02 '26	Proposed Sale	34.57	61,200	2,115,674		Feb 02 04:05 PM
Hopkinson Craig C.	Officer	Feb 02 '26	Proposed Sale	33.93	9,000	305,384		Feb 02 04:02 PM
Hopkinson Craig C.	Officer	Jan 08 '26	Proposed Sale	30.00	5,000	150,005		Jan 08 07:38 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 08 '26	Option Exercise	19.34	5,000	96,700	66,740	Jan 08 05:23 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 08 '26	Sale	30.00	5,000	150,005	61,740	Jan 08 05:23 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Jan 02 '26	Sale	28.00	4,000	112,000	61,740	Jan 02 04:39 PM
Hopkinson Craig C.	Officer	Jan 02 '26	Proposed Sale	28.00	4,000	112,000		Jan 02 04:36 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 03 '25	Option Exercise	19.34	3,748	72,486	69,488	Dec 05 04:21 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 03 '25	Sale	30.00	3,748	112,447	65,740	Dec 05 04:21 PM
Hopkinson Craig C.	Officer	Dec 03 '25	Proposed Sale	30.00	3,748	112,447		Dec 03 04:32 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Dec 01 '25	Sale	29.30	4,000	117,200	65,740	Dec 01 05:41 PM
Hopkinson Craig C.	Officer	Dec 01 '25	Proposed Sale	29.30	4,000	117,200		Dec 01 04:45 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 03 '25	Option Exercise	19.34	5,000	96,700	78,740	Nov 03 04:37 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Nov 03 '25	Sale	30.38	9,000	273,442	69,740	Nov 03 04:37 PM
Hopkinson Craig C.	Officer	Nov 03 '25	Proposed Sale	30.38	9,000	273,442		Nov 03 04:35 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Oct 15 '25	Option Exercise	19.34	5,000	96,700	82,740	Oct 15 06:47 PM
Hopkinson Craig C.	EVP R&D, Chief Medical Officer	Oct 15 '25	Sale	31.53	9,000	283,776	73,740	Oct 15 06:47 PM
Hopkinson Craig C.	Officer	Oct 15 '25	Proposed Sale	31.53	9,000	283,777		Oct 15 04:07 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Jun 09 '25	Sale	31.95	3,333	106,489	89,542	Jun 10 04:39 PM
Nichols Christian Todd	SVP, Chief Commercial Officer	Jun 10 '25	Sale	31.09	3,334	103,654	86,208	Jun 10 04:39 PM
Nichols Christian Todd	Officer	Jun 10 '25	Proposed Sale	31.09	3,334	103,654		Jun 10 04:29 PM
Nichols Christian Todd	Officer	Jun 09 '25	Proposed Sale	31.95	3,333	106,489		Jun 09 04:08 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 28 '25	Sale	34.00	1,938	65,892	7,717	Feb 28 05:19 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 25 '25	Sale	35.26	3,743	131,978	7,717	Feb 25 06:38 PM
Parisi Samuel Joseph	VP, Finance (Interim PAO)	Feb 20 '25	Sale	35.69	1,327	47,361	7,717	Feb 20 05:18 PM

IDXX

Idexx Laboratories, Inc

ALKS

Alkermes plc

Upgrade your FINVIZ experience